Profile data is unavailable for this security.
About the company
Mithra Pharmaceuticals SA is a Belgian-based company active in the pharmaceutical industry. The Company is a biotech company providing solutions in a field of women’s health, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. The Company provides three development candidates built on Mithra’s estrogen platform, Estetrol (E4): Estelle, a solution for oral contraception, PeriNesta, the oral treatment targeting perimenopause and Donesta, a hormone therapy. The Company also develops and manufactures therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. The Company operates in more than 100 countries around the world and is headquartered in Liege, Belgium.
- Revenue in EUR (TTM)40.16m
- Net income in EUR-173.50m
- Incorporated1999
- Employees229.00
- LocationMithra Pharmaceuticals SARue de l'Expansion 57FLEMALLE 4400BelgiumBEL
- Phone+32 43533700
- Fax+32 43492821
- Websitehttps://www.mithracdmo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ind Swift Ltd | 55.14m | 1.56m | 13.71m | 1.67k | 8.76 | -- | 3.02 | 0.2486 | 2.63 | 2.63 | 92.94 | -127.54 | 0.7705 | 3.66 | 3.91 | -- | 2.18 | -0.902 | 60.58 | -- | 44.02 | 45.72 | 2.83 | -1.44 | 0.8668 | 0.3401 | 3.14 | -- | 22.21 | 11.68 | -45.34 | 11.68 | 15.24 | -- |
| Medicamen Organics Ltd | 2.77m | 263.93k | 14.03m | 112.00 | 53.14 | 8.41 | 40.90 | 5.06 | 2.05 | 2.05 | 21.60 | 12.98 | -- | -- | -- | 2,256,402.00 | -- | -- | -- | -- | 42.12 | -- | 9.51 | -- | 0.9695 | 7.04 | 0.4546 | -- | 14.11 | -- | 91.93 | -- | -- | -- |
| Immuron Ltd | 2.20m | -2.39m | 14.03m | 6.00 | -- | 1.30 | -- | 6.37 | -0.017 | -0.017 | 0.0157 | 0.0769 | 0.1664 | 0.6468 | 7.92 | 596,106.70 | -18.06 | -27.48 | -19.86 | -29.58 | 80.87 | 77.52 | -108.52 | -296.64 | 7.79 | -2.85 | 0.0023 | -- | 135.85 | -13.34 | -32.66 | -- | 3.27 | -- |
| Talphera Inc | 597.41k | -13.13m | 14.35m | 15.00 | -- | 0.9571 | -- | 24.01 | -0.8945 | -0.8863 | 0.0368 | 0.9612 | 0.0237 | -- | -- | 43,400.00 | -51.96 | -22.60 | -67.70 | -28.55 | -- | -- | -2,197.39 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Mithra Pharmaceuticals SA | 40.16m | -173.50m | 14.45m | 229.00 | -- | -- | -- | 0.3599 | -2.51 | -2.51 | 0.6363 | -1.49 | 0.1102 | 0.4452 | 0.777 | -- | -47.60 | -22.24 | -70.17 | -27.69 | 45.34 | 73.13 | -432.08 | -199.11 | 0.4339 | -3.07 | 2.01 | -- | -40.06 | -7.05 | -191.01 | -- | -- | -- |
| Regent Pacific Group Ltd | 290.81k | -22.98m | 15.03m | 17.00 | -- | -- | -- | 51.69 | -0.8687 | -0.8687 | 0.011 | -0.053 | 0.0218 | -- | 12.19 | 145,588.80 | -172.08 | -50.00 | -694.26 | -59.04 | -- | -- | -7,901.89 | -2,685.21 | -- | -- | -- | -- | 574.47 | -44.72 | 31.24 | -- | -50.60 | -- |
| BioMaxima SA | 11.34m | 84.11k | 15.39m | 115.00 | 181.31 | 1.40 | 21.17 | 1.36 | 0.0869 | 0.0869 | 11.68 | 11.22 | 0.6653 | 1.88 | 4.77 | 423,217.40 | 0.4935 | 16.44 | 0.5661 | 22.44 | 48.78 | 40.72 | 0.7417 | 12.84 | 1.06 | 0.9304 | 0.214 | -- | -67.22 | 9.13 | -97.97 | -- | 0.7404 | -- |
| Holder | Shares | % Held |
|---|---|---|
| BNP Paribas Asset Management Belgium SAas of 30 Jun 2024 | 359.75k | 0.52% |
| BNP Paribas Asset Management Europe SASas of 29 Nov 2023 | 111.92k | 0.16% |
| State of Wisconsin Investment Boardas of 31 Dec 2022 | 4.88k | 0.01% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 516.00 | 0.00% |
| CAPFI DELEN Asset Management NVas of 31 Mar 2023 | 0.00 | 0.00% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 0.00 | 0.00% |
| DNCA Finance SAas of 31 Mar 2023 | 0.00 | 0.00% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
| Mercer Global Investments Europe Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
| Anphiko Asset Management SAas of 30 Jun 2023 | 0.00 | 0.00% |
